Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear receptor subfamily 1, group H, member 3 | Starlite/ChEMBL | References |
Homo sapiens | nuclear receptor subfamily 1, group H, member 2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Onchocerca volvulus | Bile acid receptor homolog | Get druggable targets OG5_134445 | All targets in OG5_134445 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_134445 | All targets in OG5_134445 |
Brugia malayi | ecdysteroid receptor | Get druggable targets OG5_134445 | All targets in OG5_134445 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | photoreceptor-specific nuclear receptor | nuclear receptor subfamily 1, group H, member 3 | 387 aa | 321 aa | 28.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | ingi protein (ORF1) | 0.0102 | 0.0309 | 0.0309 |
Echinococcus multilocularis | ribonuclease H1 | 0.0094 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0207 | 0.438 | 0.5 |
Echinococcus granulosus | ribonuclease H1 | 0.0094 | 0 | 0.5 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0207 | 0.438 | 1 |
Trichomonas vaginalis | ribonuclease H1, putative | 0.0094 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0102 | 0.0309 | 0.0309 |
Trypanosoma brucei | retrotransposon hot spot protein 4 (RHS4), interrupted | 0.0102 | 0.0309 | 0.0309 |
Trypanosoma cruzi | ribonuclease H1, putative | 0.0094 | 0 | 0.5 |
Giardia lamblia | Ribonuclease H | 0.0094 | 0 | 0.5 |
Trypanosoma brucei | ingi protein (ORF1) | 0.0102 | 0.0309 | 0.0309 |
Brugia malayi | ecdysteroid receptor | 0.0207 | 0.438 | 1 |
Leishmania major | ribonuclease H1, putative | 0.0094 | 0 | 0.5 |
Trypanosoma cruzi | ribonuclease H1, putative | 0.0094 | 0 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.0352 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | ribonuclease HI | 0.0094 | 0 | 0.5 |
Toxoplasma gondii | ribonuclease HI protein | 0.0094 | 0 | 0.5 |
Treponema pallidum | ribonuclease H (rnhA) | 0.0094 | 0 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0102 | 0.0309 | 0.0309 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | 0 uM | Effective concentration in transactivation assay using a chimeric LXR construct in HEK-293 cells for LXRalpha receptor | ChEMBL. | 16125384 |
EC50 (binding) | 0 uM | Effective concentration in transactivation assay using a chimeric LXR construct in HEK-293 cells for LXRbeta receptor | ChEMBL. | 16125384 |
EC50 (binding) | = 3.1 uM | Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay | ChEMBL. | 16125384 |
EC50 (binding) | = 3.1 uM | Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay | ChEMBL. | 16125384 |
EC50 (binding) | > 50 uM | Effective concentration in recombinant human LXRbeta ligand binding domain in homogeneous time-resolved fluorescence assay | ChEMBL. | 16125384 |
EC50 (binding) | > 50 uM | Effective concentration in recombinant human LXRbeta ligand binding domain in homogeneous time-resolved fluorescence assay | ChEMBL. | 16125384 |
IC50 (binding) | = 3.1 uM | Inhibitory concentration in LXRSPA alpha binding assay | ChEMBL. | 16125384 |
IC50 (binding) | = 3.1 uM | Inhibitory concentration in LXRSPA alpha binding assay | ChEMBL. | 16125384 |
IC50 (binding) | = 4.12 uM | Inhibitory concentration in LXRSPA beta binding assay | ChEMBL. | 16125384 |
IC50 (binding) | = 4.12 uM | Inhibitory concentration in LXRSPA beta binding assay | ChEMBL. | 16125384 |
Induction (binding) | = 2.2 | TA max fold induction against LXR alpha | ChEMBL. | 16125384 |
Induction (binding) | = 2.8 | TA max fold induction against LXR beta | ChEMBL. | 16125384 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.